GSK slashes ReQuip price in U.K. by 60%
GlaxoSmithKline cut the U.K. price of Parkinson's treatment ReQuip XL by 60 percent, making it less expensive than competing dopamine agonists. Report
THE LIBRARY: WEBINAR
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Latest Commentary
EVENTS
- MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
- Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
- What's your BIO?June 18-21, 2012 — Boston, MA
Press Releases
- Recipharm secures financing for future growth
- PPD Names David Simmons Chairman and CEO
- Pfizer Names Olivier Brandicourt as President and General Manager, Emerging Markets and Established Products Business Units
- PPD Names David Simmons Chairman and CEO
- NICE recommends new treatment option for people with common heart condition
- More Press Releases
Featured Jobs
-
Sr. Manager, Patient Marketing
Vivus, Inc. - Mountain View, CA -
Quality Assurance Scientist Job
Yoh - Brea, CA, USA -
Sr. IT Infrastructure Architect Job
Celgene Corporation - Berkeley Heights, NJ, US -
Oncology Knowledge Lead
Merck - Boston, MA -
Clinical Trial Manager
TESARO - Waltham, MA
Comments